Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7939)
All Articles published online
|
Publishing Process of This Article
|
Dec 7, 2015 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Hsu PI, Lin PC, Graham DY. Hybrid therapy for |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i45/12954.htm |
| Number | Citing Articles |
| 1 |
Ping-I Hsu, Kuan-Yang Chen, Wei-Chen Tai, Jyh-Chin Yang, Feng-Woei Tsay, Yu-Hwa Liu, Chien-Lin Chen, Chia-Long Lee, Hong-Zen Yeh, Chao-Hung Kuo, Seng-Kee Chuah, Hsi-Chang Lee, Chang-Bih Shie, Sz-Iuan Shiu, John Y. Kao, Yoshio Yamaoka, David Y. Graham, Deng-Chyang Wu. Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. American Journal of Gastroenterology 2023; 118(7): 1184 doi: 10.14309/ajg.0000000000002255
|
| 2 |
Jyh‐Ming Liou. Optimization of Helicobacter pylori eradication therapies. Advances in Digestive Medicine 2018; 5(1-2): 1 doi: 10.1002/aid2.13065
|
| 3 |
Ping‐I Hsu, Feng‐Woei Tsay, John Y Kao, Nan‐Jing Peng, Kuo‐Wang Tsai, Tzung‐Jiun Tsai, Chao‐Hung Kuo, Sung‐Shuo Kao, Huay‐Min Wang, Yan‐Hua Chen, Chang‐Bih Shie, Deng‐Chyang Wu. Equivalent efficacies of reverse hybrid and concomitant therapies in first‐line treatment of Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 2020; 35(10): 1731 doi: 10.1111/jgh.15034
|
| 4 |
Abdelrahman Y. Sherif, Gamaleldin I. Harisa, Ahmad A. Shahba, Fahd A. Nasr, Ehab I. Taha, Ali S. Alqahtani. Assembly of nanostructured lipid carriers loaded gefitinib and simvastatin as hybrid therapy for metastatic breast cancer: Codelivery and repurposing approach. Drug Development Research 2023; 84(7): 1453 doi: 10.1002/ddr.22097
|
| 5 |
Fu-Wei Wang, Su-Chi Young, Ru-Yih Chen, Kung-Hung Lin, Yan-Hua Chen, Ping-I Hsu, Hsien-Chung Yu. The Prevalence and Risk Factors of Gastric Polyp in Asymptomatic Patients Receiving Health Examination. Gastroenterology Research and Practice 2018; 2018: 1 doi: 10.1155/2018/9451905
|
| 6 |
Elizabeth A. Marcus, George Sachs, David R. Scott. Eradication of Helicobacter pylori Infection. Current Gastroenterology Reports 2016; 18(7) doi: 10.1007/s11894-016-0509-x
|
| 7 |
Sotirios Georgopoulos, Vasilios Papastergiou. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opinion on Pharmacotherapy 2021; 22(6): 729 doi: 10.1080/14656566.2020.1845649
|
| 8 |
Li Zhao, Wenqiang Liao, Guibin Lin, Jianmin Yang, Xianai Shi, Yunquan Zheng. Rubropunctatin-silver composite nanoliposomes for eradicating Helicobacter pylori in vitro and in vivo. International Journal of Pharmaceutics 2024; 649: 123655 doi: 10.1016/j.ijpharm.2023.123655
|
| 9 |
Lyudmila Boyanova, Petyo Hadzhiyski, Nayden Kandilarov, Rumyana Markovska, Ivan Mitov. Multidrug resistance inHelicobacter pylori: current state and future directions. Expert Review of Clinical Pharmacology 2019; 12(9): 909 doi: 10.1080/17512433.2019.1654858
|
| 10 |
Chih-An Shih, Chang-Bih Shie, Ping-I Hsu. Update on the first-line treatment of Helicobacter pylori infection in areas with high and low clarithromycin resistances. Therapeutic Advances in Gastroenterology 2022; 15: 175628482211381 doi: 10.1177/17562848221138168
|
| 11 |
Wei-Chen Tai, Shih-Cheng Yang, Chih-Chien Yao, Cheng-Kun Wu, An-Che Liu, Chen-Hsiang Lee, Yuan-Hung Kuo, Seng-Kee Chuah, Chih-Ming Liang. The Efficacy and Safety of 14-day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14-day Rabeprazole-Containing Hybrid Therapy for the Naïve Helicobacter pylori Infection in Taiwan: A Randomized Controlled Trial. Infectious Diseases and Therapy 2023; 12(5): 1415 doi: 10.1007/s40121-023-00811-3
|
| 12 |
Javier P. Gisbert, Adrian G. McNicholl. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter 2017; 22(4) doi: 10.1111/hel.12392
|
| 13 |
Jyh-Ming Liou, Po-Yueh Chen, Yu-Ting Kuo, Ming-Shiang Wu. Toward population specific and personalized treatment of Helicobacter pylori infection. Journal of Biomedical Science 2018; 25(1) doi: 10.1186/s12929-018-0471-z
|
| 14 |
Yi Hu, Yin Zhu, Nong-Hua Lu. Recent progress in Helicobacter pylori treatment. Chinese Medical Journal 2020; 133(3): 335 doi: 10.1097/CM9.0000000000000618
|
| 15 |
Anthony O'Connor, Wolfgang Fischbach, Javier P. Gisbert, Colm O'Morain. Treatment of Helicobacter pylori infection 2016. Helicobacter 2016; 21(S1): 55 doi: 10.1111/hel.12342
|
| 16 |
G L Yurenev, E V Partzvania-Vinogradova, D N Andreev, D T Dicheva, I V Maiev. Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection. Terapevticheskii arkhiv 2018; 90(8): 33 doi: 10.26442/terarkh201890833-39
|
| 17 |
Ping‐I Hsu, Chao‐Yu Pan, John Y Kao, Feng‐Woei Tsay, Nan‐Jing Peng, Sung‐Shuo Kao, Yan‐Hua Chen, Tzung‐Jiun Tsai, Deng‐Chyang Wu, Kuo‐Wang Tsai. Short‐term and long‐term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota. Journal of Gastroenterology and Hepatology 2019; 34(11): 1968 doi: 10.1111/jgh.14736
|
| 18 |
Abstract(191) |
Core Tip(124) |
Full Article(HTML)(296)
|
全文 (PDF)-1522K(149)
|
Times Cited (0)
|
Total Visits (760)
|
Open
|
| 19 |
Li-Yuan Yu, Lu-Ning Sun, Xue-Hui Zhang, Yue-Qi Li, Lei Yu, Zi-Qing-Yun Yuan, Ling Meng, Hong-Wen Zhang, Yong-Qing Wang. A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors. Advances in Therapy 2017; 34(5): 1070 doi: 10.1007/s12325-017-0532-9
|
| 20 |
Ju Yup Lee, Kyung Sik Park. Optimal First-Line Treatment forHelicobacter pyloriInfection: Recent Strategies. Gastroenterology Research and Practice 2016; 2016: 1 doi: 10.1155/2016/9086581
|
| 21 |
Feng-Woei Tsay, Deng-Chyang Wu, Hsien-Chung Yu, Sung-Shuo Kao, Kung-Hung Lin, Jin-Shiung Cheng, Huay-Min Wang, Wen-Chi Chen, Wei-Chih Sun, Kuo-Wang Tsai, Ping-I Hsu. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. Antimicrobial Agents and Chemotherapy 2017; 61(11) doi: 10.1128/AAC.00140-17
|
| 22 |
Ignasi Puig, Mireia Baylina, Jordi Sánchez-Delgado, Sheila López-Gongora, David Suarez, Pilar García-Iglesias, Neus Muñoz, Javier P. Gisbert, Cristina Dacoll, Henry Cohen, Xavier Calvet. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole forHelicobacter pylorifirst-line treatment. Journal of Antimicrobial Chemotherapy 2016; 71(10): 2740 doi: 10.1093/jac/dkw220
|
| 23 |
Angel Lanas, Francis K L Chan. Peptic ulcer disease. The Lancet 2017; 390(10094): 613 doi: 10.1016/S0140-6736(16)32404-7
|
| 24 |
Lyudmila Boyanova, Petyo Hadzhiyski, Raina Gergova, Rumyana Markovska. Evolution of Helicobacter pylori Resistance to Antibiotics: A Topic of Increasing Concern. Antibiotics 2023; 12(2): 332 doi: 10.3390/antibiotics12020332
|
| 25 |
Peter H. Katelaris, Anthea L. Katelaris. A prospective evaluation of levofloxacin‐based triple therapy for refractory Helicobacter pylori infection in Australia. Internal Medicine Journal 2017; 47(7): 761 doi: 10.1111/imj.13432
|
| 26 |
Soohoon Kwon, Dong Ho Lee, Jae Bin Kang, Nayoung Kim, Young Soo Park, Cheol Min Shin, Hyuk Yoon, Yoon Jin Choi. The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure inHelicobacter pyloriEradication. The Korean Journal of Gastroenterology 2017; 70(2): 72 doi: 10.4166/kjg.2017.70.2.72
|
| 27 |
Zhi-Qiang Song, Jian Liu, Li-Ya Zhou. Hybrid Therapy Regimen for Helicobacter Pylori Eradication. Chinese Medical Journal 2016; 129(8): 992 doi: 10.4103/0366-6999.179803
|
| 28 |
Chih-Chieh Huang, Kuo-Wang Tsai, Tzung-Jiun Tsai, Ping-I Hsu. Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy. Biomarker Research 2017; 5(1) doi: 10.1186/s40364-017-0103-x
|
| 29 |
Yi Hu, Yaobin Ouyang, Yin Zhu, Nong‐Hua Lu. Reverse hybrid therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis. Helicobacter 2021; 26(2) doi: 10.1111/hel.12784
|
| 30 |
Caiqi Liu, Yuan Wang, Jiaqi Shi, Chunhui Zhang, Jianhua Nie, Shun Li, Tongsen Zheng. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therapeutic Advances in Gastroenterology 2021; 14: 175628482198917 doi: 10.1177/1756284821989177
|
| 31 |
Yongkang Lai, Wei Wei, Yiqi Du, Jie Gao, Zhaoshen Li.
Biomaterials for
Helicobacter pylori
therapy: therapeutic potential and future perspectives
. Gut Microbes 2022; 14(1) doi: 10.1080/19490976.2022.2120747
|
| 32 |
Tsung-Jung Lin, Hsi-Chang Lee, Chih-Lin Lin, Chung-Kwe Wang, Kuan-Yang Chen, Deng-Chyang Wu. CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for <i>Helicobacter pylori</i> eradication. World Journal of Clinical Cases 2018; 6(12): 514-520 doi: 10.12998/wjcc.v6.i12.514
|
| 33 |
Shivaram Prasad Singh, Vineet Ahuja, Uday C. Ghoshal, Govind Makharia, Usha Dutta, Showkat Ali Zargar, Jayanthi Venkataraman, Amit Kumar Dutta, Asish K Mukhopadhyay, Ayaskanta Singh, Babu Ram Thapa, Kim Vaiphei, Malathi Sathiyasekaran, Manoj K. Sahu, Niranjan Rout, Philip Abraham, Prakash Chandra Dalai, Pravin Rathi, Saroj K. Sinha, Shobna Bhatia, Susama Patra, Ujjala Ghoshal, Ujjal Poddar, Venigalla Pratap Mouli, Vikram Kate. Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology. Indian Journal of Gastroenterology 2021; 40(4): 420 doi: 10.1007/s12664-021-01186-4
|
| 34 |
Maria José Temido, Dara Mbanze, Nuno Almeida, Bárbara Oliveiros, Elisa Gravito-Soares, Pedro Figueiredo. Is hybrid therapy more efficient in the eradication of Helicobacter pylori infection? A systematic review and meta-analysis. Annals of Clinical Microbiology and Antimicrobials 2023; 22(1) doi: 10.1186/s12941-023-00582-2
|